SERIF
Live / Applied — First extension granted (statement of use) (as of 17 Oct 2025)
What this means for you
Not registered yet, but its 09 Jul 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98638645
- Mark type
- Stylized text
- Filed
- 09 Jul 2024
- Published for opposition
- 25 Feb 2025
- Attorney of record
- Christina M. Licursi
Goods and services
- Class 001 — Chemicals: Biological and chemical agents for scientific and research use, namely, nucleic acids for use in the manufacture of pharmaceuticals, reagents for pharmaceutical research purposes, and cells for scientific and research use
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; therapeutic pharmaceutical for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; pharmaceutical preparations, namely, DNA therapeutics for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases
- Class 042 — Scientific and technological services: Drug development services, namely, pharmaceutical drug development services; scientific research, namely, research and analysis services for the design and characterization of biologic therapeutic products, namely, pharmaceutical drug development services; pharmaceutical and biotech research and development, namely, pharmaceutical drug development services
Owner
- SERIF BIOMEDICINES, INC., CAMBRIDGE, MA, US
- SERIF BIOMEDICINES, INC., CAMBRIDGE, MA, US
- Flagship Labs 87, Inc., Cambridge, MA, US
Prosecution history
- 18 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 17 Oct 2025 — SOU EXTENSION 1 GRANTED
- 17 Oct 2025 — SOU EXTENSION 1 FILED
- 17 Oct 2025 — SOU TEAS EXTENSION RECEIVED
- 22 Apr 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 25 Feb 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 25 Feb 2025 — PUBLISHED FOR OPPOSITION
- 19 Feb 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 30 Jan 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 29 Jan 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 29 Jan 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 29 Jan 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 02 Jan 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 02 Jan 2025 — NON-FINAL ACTION E-MAILED
- 02 Jan 2025 — NON-FINAL ACTION WRITTEN